astrazeneca pausing the late-staged vaccine trial due to an unexplained illness in one candidate. it is september 9. this is "worldwide exchange" here on cnbc >> announcer: this is cnbc breaking news market sell-off. >> good morning. good afternoon good evening thank you for joining us on an important morning. we are glad you are kicking it off with us. futures this morning are higher. the dow is up 142. it is early. nasdaq futures, they have been the one to watch they are up right now 170 points more than the dow. the markets taking another big hit yesterday. this is the continued selling we had from last week it appeared to be ramping up to begin our week here. not just with technology names the dow falling 630 points yesterday, s&p 500 closing down 100 points to end the worst and first three-session losing streak since june. big tech taking the brunt of the impact notable declines apple down nearly $8 or 7% microsoft shedding 11.5 a share, also on the rebound this morning. the stock everybody cares about that the market cares about is tesla. tesla yesterday losing $88 a share.

astrazeneca put the brakes on its vaccine trial.rchers are reviewing safety data after a participant became ill. more on that story next. this is bloomberg. ♪ ♪ manus: it is "bloomberg daybreak: europe." manus cranny in dubai, annmarie hordern alongside me. astrazeneca pushed the pause button on the vaccine trial. the company will stop giving its experimental coronavirus shots after one subject became ill. investors,n jolted sending u.s. shares of astrazeneca lower. dani burger has been tracking the pace on the pause. doubt ais is no setback, but the severity of that setback depends on whether the illness is related to the vaccine itself or something separate. if it is something separate, it could just be that, just be a delay. we certainly see markets pricing that a little bit more today as we saw a bounceback in the nasdaq futures and s&p 500 futures. if this illness is related to the vaccine itself, it threatens to derail the effort for astrazeneca, which is a leading candidate right now for a vaccine. if it is a delay, we are se

coming up, astrazeneca puts the brakes on its vaccine trial.hers are reviewing safety data after a participant became ill. more on that story next. this is bloomberg. ♪ ♪ francine: you are watching "bloomberg surveillance." stopped aa has late stage trial of its corona vaccine after a participant became ill. the drugmaker said the decision was a routine action intended to allow researchers to examine safety data. but it could also delay or derail efforts to deliver the so-called oxford vaccine, which is seen as one of the leading candidates to provide immunization against covid-19. joining us now with the very reporter our pharma from bloomberg intelligence. how likely was it that something like this would happen? how much of a shock is it? >> in these large trials, there is always a risk of these assorted safety side effects, especially when you are dealing with a new vaccine, a new technology, and the heightened awareness of these trials, given that you are giving them to healthy volunteers, so not surprised. francine: what is the biggest con

adam, thanks again >>> meg, we very much appreciate it and astrazeneca down today -- a lot of vaccinerallying after that report >>> could a different cut be on the table? peloton is up double digits this week as wall street gets even more bullish on the stock. should you cseha the gains traders weigh in, after this quick break. it's easy to get lost in the economic uncertainty. the volatility. the ambiguity. the moment calls for more. and northern trust delivers more. with specialized expertise. proven strategies rooted in data and analytics... and insights borne from over 130 years of successfully navigating economic turbulence. giving you clarity. inspiring confidence. and helping you uncover new paths forward. northern trust. wealth management. for skin as alive as you are... don't settle for silver ♪ gold bond champion your skin >>> one question is which trends will last into the fall and wind price targets are being boosted for peloton, even as gyms reopen, demand for their products will remain strong. it call 11 price bumps, as shares have rallied more than 200% this years. let'

astrazeneca pausing the late-staged vaccine trial due to an unexplained illness

>>> astrazeneca, they have just paused all of their testing worldwide after an unexplained illness in one volunteer in britain. >> no one controls the timeline on these vaccine developments. we're at the mercy of nature. >> they're doing their due diligence. you want to see this. this is how the system is supposed to work. >> when you look at these images of the rallies, this is the sort of events you're trying stroto avoid. >> i really believe these crowds are bigger than there were four years ago. >> we've pushed our curves down, saved throws of lives, and events like this threaten all that progress that we've made. >> we want to welcome our viewers in the united states and all around the world. this is "new day." and there has been a setback in the search for a coronavirus vaccine. astrazeneca pausing its phase iii clinical trial here and overseas because of an unexplained illness in a study participant. as of this morning, the number of new coronavirus case appears to have leveled off, but leveled off at 40,000 a day. we're also learning more than half a million children in the u.

let's get the latest on the vaccine and applause announced by astrazeneca but we have no idea why, it could be reaction to the vaccine or reaction to the placebo or something completely else, this is a routine pause and we should not read too much into it. is that correct? >> yes, obviously astrazeneca took a big hit this morning and the other vaccines in the works are seen increases in their companies and i'll talk about

but they can't comment right now, since all inquiries must be deferred to astrazeneca. the final stages of astrazeneca's covid-19 vaccine trials are on hold after a volunteer became ill. in a statement sent to abc 7 the company said they voluntarily caused vaccination to review safety data, which has to happen whenever there is a potentially unexplained illness in one of the trials. a source says the affected patient is in the uk, where astrazeneca is based. >> it is reason to be concerned, but it's not unusual thathi would ham, especially with enrolling thousands and thousands of patients. >> reporter: dr. yvonne maldonado is a stanford epidemiologist. she's not part of the astrazeneca trial but she's conducted clinical vaccine trials all over the world. >> the only reason you need to do this trial these ways is because of exactly this reason. it's possible that the safety signal will be determined to be unrelated and they can move forward. >> reporter: last month abc 7 got an inside look at a san francisco trial site for the astrazeneca vaccine. the bay area trial was

coming up, astrazeneca taps the brakes on its vaccine trial.esearchers reviewing safety data after a participant became ill. more on that story next. what to watch for this morning. this is bloomberg. ♪ matt: welcome back to bloomberg markets, this is the european open. we are 49 minutes away from the cash equity trade. you're looking at red arrows in terms of european futures. let's get to bloomberg first word news, we go to laura wright in london. laura: thanks, matt. astrazeneca has paused a late stage trial of its coronavirus vaccine after a participant became ill. the drugmaker said the decision was a routine action intended to allow researchers to examine safely data. it could delay or derail efforts to deliver the so-called oxford vaccine, which is seen as one of the leading candidates to provide immunization against covid-19. high yield bond defaults could struggle, according to jeffrey goodlatte who criticized the fed's actions, accusing them of uh unsustainable corporate brings. deutsche bank said the best run of stocks and bonds in 1

astrazeneca's u.s.ter the british drugmaker's phase 3 coronavirus vaccine trial was put on hold. the vaccine is being developed with oxford university. statementy says in a the pause is a routine action after one of the trial dispense fell ill -- participants fell ill. it is working to keep the trial moving. senate majority leader mitch mcconnell is working on a vote for the latest u.s. to millis package as early as -- stimulus package as early as this week. the democrats are looking for at least three times the amount. house speaker nancy pelosi told bloomberg the package is nowhere near enough. pelosi: what they have is so meager that it insults the intelligence of the american people. it does not solve the problem and -- again, we know we have to compromise. we know we have to negotiate to reach an agreement. we all want an agreement, make no mistake, but get real, mitch mcconnell. karina: global news 24 hours a day on air and on quicktake on twitter, powered by more than 2700 journalists and analyst

astrazeneca starting their trial.r's ceo saying we could get inoculation before the end of the year. yields, 0.6%. we have the fed this week. ♪ so you're a small business, or a big one. you were thriving, but then... oh. ah. okay. plan, pivot. how do you bounce back? you don't, you bounce forward, with serious and reliable internet. powered by the largest gig speed network in america. but is it secure? sure it's secure. and even if the power goes down, your connection doesn't. so how do i do this? you don't do this. we do this, together. bounce forward, with comcast business. >> good morning from bloomberg's european headquarters in the city of london, i'm annmarie hordern with manus cranny live from dubai. it is m&a monday. oracle to have won a deal for tiktok she was operation. plumps up the cash to boost cancer focus. the u.s. couldys get a covid-19 vaccine before year's end and astrazeneca resumes its trial after last year's halt. a growingson faces rebellion as his controversial bill is debated in parliament. bru

astrazeneca then called this incorrect and said there was no final diagnosis.zeneca's own internal initial safety report obtained by cnn says the participant had, quote, experienced confirmed transverse myelitis and, quote, symptoms consistent with transverse milits. the report describes how the participant, a 37-year-old woman in the uk, was previously healthy. she had two doses of the coronavirus vaccine about two and a half months apart. then on september 2nd, 13 days after that second dose, while running, she had a trip, not a fall, with a jolt according to the report. the next day, she experienced symptoms including difficulty walking, pain and weakness in her arms. on september 5th, she was hospitalized and a neurologist noted that her symptoms were improving. citing patient confidentiality, astrazeneca declined to provide more details about the woman's case. so did the university of oxford which is running the trials in the uk. on september 11th, astrazeneca distributed its report to doctors involved with its study. that same day the university of oxford

the astrazeneca trials are on hold after a volunteer became ill.at this means for the bay area trials which were about to begin. >>> south bay business owners find ways to reopen indoors, but they know that opportunity could slam shut again. abc 7 news starts right now. >>> building a better bay area for a safe and secure future. this is abc 7 news. >>> tonight across the tales of harrowing escapes from ravaging wildfires. skies darken. thousands face another night without electricity. power shut off to prevent park sparking any new fires. more than 167,000 pg&e customers in fact in 21 counties are still without power. >> this map shows the current public safety power shutoffs. they're indicated by upside down purple triangles. and dan, right now utility crews are inspecting lines and working to restore power in some of these areas. >> reporter: that's right-a ma. they're working fast as you know. j.r. stone is in calistoga where entire neighborhoods are still in the dark tonight. >> reporter: complete darkness along these neighborhood streets on t

but followed up with astrazeneca to get more details. top of all of that for us let's get to mike taking a look at economic trends and whether or not that's showing improvement. >> straed improvement. tech stocks, under the surface this has been going on in terms of improving trend this is goldman sachs reopening index. it's at a high all the way back to march this uptick is labor day weekend. might be a downtick based on the timing this essentially says 72% of the preshutdown levels in terms of reopening, restaurants, movie going, mobility, retail, take a look at gdp tracking it doesn't look quite as bright but also has bounce significantly. the fed produces this on a weekly basis a downtick, might be labor day, end of august. that's a sharp rebound how much more are we going to recover. till down 4% at this point on year over year basis look at the liquidity backdrop we have an economy that's starting to bounce and recover in terms of overall policy, monetary, fiscal, credit, what the foreign exchange markets are doing, all that togeth

astrazeneca, j & j, pfizer and merck has one. to play a trading view of it, moderna has had a big pullback i think we're going to hear from this data in the next month or two. i think they go back up a bit. the longer term question will come back. that's ultimately going to be the debate of what does it matter if more are coming. the price is going to go down and we're going to go back to that debate. >> tim seymour, how do you think about the disclosures and the company's denial from astrazeneca? >> it sounds to me like disclosure is really the issue, because it is customary to be pausing a trial and going through a series of steps to understand exactly what the safety issues are. i thought ken frazier said this really well. you can't rush science ultimately i get the sense these big pharma companies are doing their jobs but the disclosure and how you get into a reg fd dynamic on a conference call with investors who keep pressing is a very challenging place, although for an experienced ceo to be able to handle markets didn't act

astrazeneca called reports incorrect and said there was no final diagnosis.ca's own internal initial safety report obtained by cnn says the participant had, quote, experienced confirmed transverse myelitis and, quote, symptoms consistent with transverse myelitis. the show had two doses of the coronavirus vaccine about 2.5 months apart. then on september 2nd, 13 days after that second dose while running she had a trip, not a fall with a jolt. the next day she experienced symptoms including difficulty walking, pain and weakness in her arms. on september 5th she was hospitalized and a neurologist noted her symptoms were improving. as tra seven astrazeneca declined to provide more details so did the university of oxford running the trials in the u.k. on september 11th, astrazeneca distributed report to doctors involved with the study. that same day the university of oxford updated this online patient information sheet that says volunteer the trial developed unexplained neurological symptoms including changed sensation or limb weakness. it does not mention myeliti

what did astrazeneca say about those reports? >> so astrazeneca said that media reports of confirmed transverse myelitis were inaccurate, were incorrect. and they said that there was no final diagnosis. so that's led many people to say, wait a minute, where's the transparency? you know, we need more transparency. this is something that is being funded by taxpayers to a large extent. astrazeneca got a large chunk of money from operation warp speed and this is a vaccine that many of us, you know, hundreds of millions of else might end up taking and there are people calling for more transparency in this whole process. >> elizabeth, thank you very, very much for that. >>> let's talk about all of the developments and they're significant. dr. leana wen is here. good morning, doctor. >> good morning. >> so let's just -- i'd love your opinion on the health consequences of the president neutering the cdc with those comments and then on top of michael caputo, the former hhs spokesperson accusing government scientists of sedition and saying

we heard from astrazeneca after the close.e already had some skepticism over what happened to those vaccine approvals. we also had the text selloff accelerating. . we saw the s&p 500 sinking to a four week low. not to mention ongoing u.s.-china tensions. every sector on the s&p 500, 11 of them were down, led by tack and energy. we had the nasdaq composite losing more than 4% during the regular session. take a look at some of the biggest decliners. we have tesla sinking almost 20%. this after shares were not added to the s&p 500. a had news that rival gm took $2 billion equity stake in nikola. 6%,e losing more than wiping out more than $120 billion in market value on tuesday. these tech champions of the u.s. equity valley -- equity rally under pressure. wti continuing to fall toward that $36 a barrel level. we have already seen the biggest fall in about five months. . now trading at the lowest in 14 weeks. let's see how things are shaping up with asian markets. sophie: stocks in asia are said to decline. panic may be unlikely a

this is astrazeneca doing their due diligence.ng at the adverse event, looking to what happened the person with the unexplained illness. going back through their data to see if perhaps they sought elsewhere. was an assistant professor at johns hopkins. school isinder, that supported by michael bloomberg. reporting 17e is covid-19 deaths over the past 24 hours. again, trending in the right direction as the state remains under a strict lockdown. moment.ing news at the we are now hearing that brookfield and simon have agreed fory j.c. penney assets $1.75 billion. 118-year-oldthe j.c. penney retailer had plunged into bankruptcy proceedings after the pandemic forced it to close more than 800 stores. j.c. penney is saying that this -- that it will also include cash and new debt. a duo of mall owners are now carrying on with buying j.c. penney assets for $1.75 billion. let's get a quick check of the markets. we are seeing u.s. futures reversing earlier losses. 500 as we have the s&p seeing its best day since june. kiwi stocks gaining. in

we are seeing that with the astrazeneca vaccine.al editor. getting to the open in india. let's have a look at how things are going in mumbai. looks like we have a positive start to the trading day as we do in the rest of this part of the world. it is the first day we are seeing advances, declines from the last two. of thens the week options expire recession on a strong note. this is bloomberg. ♪ ♪ almost an even split. 12 out of 21 analysts expected malaysia to keep rates steady as the economy recovers. . let's get more on what to expect with michelle who joins us from singapore. what is the case for malaysia holding steady on rates today? what else could they do? >> you are right. it is a pretty slim majority. the case comes out of a few things. in each of the four decisions, they did already cut. there is an argument for allowing those to continue filtering through the economy. malaysia is not as close to zero as some others in the region. someght also want to give room for fiscal stimulus to make its room through the economy. all

so how long will this astrazeneca trial be on pause? live look over oregon as the fires there rage on, looking like a -- literally like a ring of fire in what is being called a once in a generation fire. esses... .to soccer practices... ...and new adventures. you hope the more you give the less they'll miss. but even if your teen was vaccinated against meningitis in the past... they may be missing vaccination for meningitis b. let's help protect them together. because missing menb vaccination could mean missing out on a whole lot more. ask your doctor if your teen is missing meningitis b vaccination. you should be mad your neighbor always wants to hang out. and you should be mad your smart fridge is unnecessarily complicated. make ice. making ice. but you're not mad because you have e*trade which isn't complicated. their tools make trading quicker and simpler so you can take on the markets with confidence. don't get mad get e*trade and start trading commission free today. which is breast cancer that has spread to other parts of the body

astrazeneca shares are down about 2%. vie license and unrest taking a toll in rochester, the city's police chief and entire command staff now stepping down. this as rochester police are trying to identify suspects accused of launching fireworks at law enforcement during these protests. apple steps up the legal pressure on epic games, the maker of the popular game fortnite. apple is counter suing the company for breach of contract for operating its own in-app system. it is seeking punitive damages. epic sued apple and google last month after they pulled the fortnite game from their app stores. apple and google get 30% of in-app purchases. apple shares in the premarket, trading this way, a dow component, and it is up 3 and three quarters percent. broad market positive this morning, apple lifting a few boats following yesterday's selloff. look at the bounceback this morning. the dow industrials fell better than 600 points yesterday and is rebounding this morning, 175. the nasdaq now yo in correction territory with a 465 poin

it is not just t the united stae ast the astrazeneca ask busineness as s usual.ave material information or maybe they did not consider materialal but in any event, released a few more detailsls tt selectivively to the investoror crowd. what were thosose details? said, theed, and shshe side effect that was discovered in t this one trial paparticipas consnsistent with transverse myelitis. that could be a a first sign of multiple sclerosis. a.my: also similar to dmdmr >> we need to know more information n about that. other resesearchers neeeed to k. other r companies that are using the same vaccine tech h elegy or platfo, they want to know whwhat is goioing on. does this affefect them? does this affect other people's willingness and abilitity to enroll i in one or more clclinil trials but thahat company and others?? so there are a lot of implications herere. as i said, to treat it as business as usual, thinking of the greater gogood, inststead of tryi to address concerns that can show up with lack of transparency and therefore lack of trust. amy: we just have a minu

la universidad de oxford anunciÓ que la farmacÉutica astrazeneca reanudarÁ las pruebas de las vacunas, una de las mÁs avanzadas del mundo estÁ en las fases finales. peggy: hay buenas noticias para todos los que tienen esperanzas en la aprobaciÓn de una bad una contra el coronavirus. la universidad de oxford dice que reanuda las nuevas en reino unido con la farmacÉutica astrazeneca. los ensayos habÍan sido suspendidos luego de que una voluntaria aparentemente desarrollara mielitis transversa que es una seria inflamaciÓn de la mÉdula espinal Éste médico experto en salud pÚblica dice que el esparcimiento es inusual y podrÍa no estar vinculado al estudio. >> no tenÍa nada que ver con la vacuna y la fase tres de launa desde la compaÑÍa entonces ahora pueden resumir sus estudios. >> la universidad dijo que 18,000 personas han sido vacunadas y que pruebas tan amplias es de esperarse que algunos participantes se enfermen. >> esperemos que tengan eficacia y seguridad precauciÓn pero esperamos que sÍ. podemos pensar en una vacuna para el pÚblico o los de riesgo. los ancianos, los que trabajan e

there are front runners including the astrazeneca vaccine.yesterday about astrazeneca trial being paused is a safety precaution to evaluate one of the patients. we are still waiting to hear further reports. it is the safe thing to do. we want to ensure a vaccine is both efficacious and safe. vexatious -- this vaccine race we are seeing, could it lead to a relaxing of requirements of safety? dr. vasoo: the regulations, whether it is the fda or other body, certain regulations in place to make sure and each country has jurisdictions. -- two things. one is safety, which is paramount and the other is efficacy. we do not want to release a vaccine that is in efficacious. that might lead to people presuming they are adequately protected. -- it is unlikely the vaccine will be 100% effective. if you look at the other respiratory viruses, if you'd 60%, thatetween 50 to is a very good vaccine. just really quickly, we have seen the reinfection case confirmed in hong kong. earlier, singapore this year has said you have not seen any significant mutation as

astrazeneca's u.s.ares fell after the british drugmaker coronavirus vaccine trial was put on hold. the vaccine is being developed by oxford university and is seen as a front-runner. the company says in a statement it is a routine action after one of the participants became ill. it is working to review the incident and keep the trial moving forward. there is a new twist in the divorce giving everyone a headache in europe. a new bill will be published today in the u.k. that rewrites an earlier art of the agreement already signed with e.u. in relation to britain's split with the yo -- split with europe. two senior advisors have quit. the changes would allow britain a no deal departure. trade talks resume today. europe is seeing a steady rise in new coronavirus cases as people return from holidays and the weather starts to cool. france reported 6000 cases on tuesday. spain, germany and the u.k. are also seeing a rise in new infections. england has banned social gatherings of more than six people. half a mil

have been strong to pick up on the trade in recent months and amid last week we're hearing the astrazeneca trial and it happened so i think investors are just a little bit cautious around the news flow from the sector >> thanks very much, karen let's get to the latest around tiktok oracle is set to be named as tiktok's u.s. technology partner according to a source directly familiar with the deal byte dance won't give source code to any u.s. buyers according to chinese state media. the news comes after microsoft confirmed byte dance rejected it's bid to buy operations they insisted the proposal would have been good for tiktok's users while protecting national security interests. >> chinese state media now said they will not sell tiktok's operations to oracle or microsoft or give the source code to any u.s. buyers and it comes after a person familiar with the discussions told our colleague state side that they had now chosen oracle to be tiktok's technology partner in the u.s. operations after the parent company rejected microsoft's bid to snap up it's u.s. operations. so byte dance is in ex

astrazeneca is testing a vaccine that we developed at the oxford university. it is what we call and add no virus vaccine and we can talk about the different types of covid-19 vaccines and c they are conducting large phase three trials in a number of countries, some combined phase two, phase three trials that are ongoing and what they identified was an adverse event. what we call an adverse event. that is exactly what these trials are meant tot detect. we heard through the news that one individual who received their vaccine developed a condition called transverse myelitis in this is an inflammation of the spinal cord that can be triggered by autoimmune diseases, immune system disorders and possibly by prior infections and even vaccines although we don't really understand in detail how this disease comes about but it is some type of immune reaction of the body against a part of the spinal cord. this was detected and they rightfully paused the trial and what they are going to try to do is see if there is any reasonable evidence to even suggest that this adverse e

with the oxford astrazeneca vaccine or placebo. he has lost seven family members to covid-19 and he wants to be part of the solution, no matter the cost. >> i know this is a risk is that the trial, but i would rather have us one. >> reporter: serrano was dosed on friday in lake worth, florida. >> the immune response is very encouraging. >> reporter: dr. larry boesch is the lead investigator for this trial. he says he's optimistic this vaccine is effective. >> the phase one and two trials the vaccine has been proven that not only do you get robust neutralizing antibodies to fight the coronavirus, you get a t cell response to fight off the cells that do become infected. that's crucial in fighting infections. nds says they ford has been -- are focusing on enrolling members of the african-american and latin x community who have been disproportionately affected. >> those groups of people are becoming infected at higher rates, and therefore that is a group that would highly benefit from vaccination. >> reporter: astrazeneca says it plans

astrazeneca is showing the signs is guiding the way which is what dr. fauci and others have said all along. >> you are confident you will see a vaccine before the end of the year? >> by the end of the year is the goal, yes. >> what is the discussion of seeing something around the time of the election? do you think it delays that? >> our timing is about saving lives. by the end of the year has always been the goal. of course, a safe and effective vaccine, we will take it as quickly as we can get it. protectionand border announced, or would announce, a ban on imports from many provinces in china as a result of the human rights abuses. that announcement has not come formally. are you intending to make the announcement or has there been bredthcklash against the of it? it does include a lot of products. >> i have no upcoming announcements about how publicly -- if i get more information, i will let you know. the rally in nevada has been canceled because of the governor's order. does the president have a reaction? what is what has policy about complying with a

>> reporter: well astrazeneca is saying this is routine and that's what the medical experts are saying when you have a case like this, where there's an unexplained so far illness among people who are going through trials then you put it on paw. this is a pause while they examine the safety implications. there's been a lot invested in this here in the uk by the deontay coston not just politically, by championing getting this study up and running. this was late april this year. emotionally the british people are very invested because they had seen this as a way out of the, you know, of all the confines of covid-19 and the restrictions of a lockdown, et cetera. and politically the government has put a lot on the line here as well. we have the health secretary in the uk just a couple of days ago saying that 30 million doses of this vaccine would be ready for early next year. the government has paid up for that. so at a medical level we're being told this is routine. emotionally ting because the country is about to go into a new level of lockdown this will be a big blow. remembering phase o

astrazeneca before this is in phase three. backdrop and what happened with astrazeneca, what is your best estimate for when a safe vaccine will be available? dr. redfield: one thing i have learned is the cdc director, i business.the opinion i'm in the data and signs of it. >> what does the data and signs suggest? dr. redfield: based on enrollment right now that is going on with the pfizer and moderna, that it is conceptual that they will have enough data to present it to the fda for evaluation somewhere before the end of october and the end of november. the reason i cannot be more specific is because these trials are event driven trials. they are 100% dependent on how much covid occurs in the volunteer population. if it is a lot of these individuals having to get covid independent of what group they are in, and the potential for them to have enough events if the vaccine is very efficacious will be in the october timeframe. if the vaccine is 50% efficacious, it might be in the late november timeframe. if there are fewer events

against the backdrop and what astrazeneca, what your best estimate for a safe vaccine being available. >> one thing i learned i'm into data and science. >> when does the data and science exist. >> based on enrollment right now going on with pfizer in madrona that is conceptual that they will have enough data to presented to the fda for evaluation somewhere before the end of october and the end of november. the reason i cannot be more specific because these trials are event driven trials in the really 100% dependent on how much covid occurs in the volunteer population. if it's a lot of the individuals or just the total number of events than the potential for them to have enough events if the vaccine will be in october timeframe and if the vaccine is 50% and might be in the late november timeframe and if there are fewer events in a very good vaccine and might be in late november, december timeframe. i think we can all say somewhere between the end of october and the end of the year it is probable one or more will be presented to the fda law review for an emergency authorization or poten

against the backdrop and this happened from astrazeneca what is your best estimate with a safe vaccine being available. >> one thing i learned is a cdc director, i'm not in the opinion business i'm in the data and science. >> when does the data suggest. >> based on what's going on with pfizer imager not that it is conceptual and they will have enough data to present it to the fda for evaluation somewhere before the end of october and the end of november. the reason i cannot be more specific is these trials are event driven trials in the really 100% dependent on how much covid occurs in the volunteer population. if it's a lot of the individuals and they get covid depending on what group therein and the potential for them to have enough events if the vaccine will be in the october timeframe and if the vaccine is 50% it might be in late november timeframe andem if there is fewr and it might be late november - december timeframe. i think we all can say somewhere between the end of october and the end of the year. that is probable that one or more of the vaccines will be presented to the fd

so astrazeneca, again, was working on this vaccine with the university of oxford. so they have put these trials on hold at the moment as they review the safety. i should point out too, as our medical unit would tell you, it is not uncommon to pause a clinical trial. they of course need to see what the reason is, see if it is in fact this trial vaccine that could be causing that adverse reaction in a participant in the uk. obviously we'll keep a close eye on this wolf. astrazeneca is one of the nine pharmaceutical companies issuing a rare statement where they're pledging they'll follow the science and not politics as they move forward. buses, backpacks, masks, back to school in the age of covid. >> my daughter is thriving to be around other people. >> it's going to be great to see them. >> reporter: 16 of the nation's largest school districts start today. of those, 14, including chicago, will begin the year online. >> as we said from day one, we're going to be guided by what the public health numbers tell us. >> reporter: the first day in hartford, connecticut, post

it was interesting, hearing from the astrazeneca chief executive.'s why you get up in the morning. is putting safety first and he can still deliver a vaccine by the end of the year. tom: it is nice to see the buzz one day on. -- for sally

astrazeneca is working with oxford university to develop the vaccine. trials in britain and brazil are in their final phase. but the drugmaker halted its trials around the world, last week, after one of the participants in britain deveveloped an unexplained illness. astrazeneca said, in a statement on saturday, that it had resumed the trials in britain after an independenent committee cononcl it was safe to do s so. the firm agreed with the japanese government, last month, to provide doses for at least 60 million people. it aims to make 50 million doses available by march of next year. >>> t turning to preparations f the tokyo olympic sqs and paralympics. organizers are looking for ways to reieign in costs. nhk has learned that final arrangements are underway to streamline plans in dozens of areas. the plan is for tokyo organizers and international olympic committee officials to reach a consensus at an ioc meeting later later this month. more than 200 areas are being examined for cost-saving measures. the organizing committee picked more than 50 of them

astrazeneca is developing the vaccine in partnership with the university of oxford.t had advanced to the final phase of development and was considered one of the front runners to secure regulatory approval. a british medical regulator said it's, quote, urgently reviewing all the information and actively engaging with the resesearcherso determine whethther the trials should restatart as quickly as possible. the pause is expected to impact japan, which had agreed in principle to secure 120 million doses from astrazeneca once the vaccine was approved. the country is also negotiating with severeral european and u.s pharmaceceutical companies to receive vaccines. meanwhile some countries appear to be rushing to offer vaccines before clinical trials are complete. in a august, russia approved a domestically developed vaccine that had not been shown to be safe and effective. in the united states, president donald trump has said a vaccine could be ready before the e endf the year, leading to specuculatn he may be putting pressure on drugmakers ahead of the upcoming election.

astrazeneca said this is not first time this trial was paused.d in july when they discovered a case of multiple scl sclerosis. now this is a matter of oxford university and astrazeneca going to the other health regulators to get the same permission before they can resume there. the ceo says despite the setback, it is still very possible to have this vaccine approved by the end of the year. it just depends how quickly health regulators can review the results of the trial once it is finished. this is not the only potential vaccine that the world is banking on. there are 35 vaccines in human trials around the world, right now, eight of them are actually in the late stages. president trump in the united states he's been hinting that a vaccine could well be approved before election day, which is raising concerns about the politization of any potential vaccine that is approved. astrazeneca was one of nine companies that signed this pledge not to cut corners, not to push for a premature approval, but despite that, a recent poll found that most americans

. >> drugmaker astrazeneca says late-stage trials of its oxford university vaccine are now on hold after one of the research participants developed an unexplained illness. >> you have to take things carefully with vaccines. they're not toys. >> joe biden heads to michigan. we expect the overarching focus to be about the economy. >> i don't know how many people here, but there's a lot. >> this is a pandemic. what you're really seeing are lemmings heading for the cliff. >> announcer: this is "new day" with alisyn camerota and john berman. >> welcome to our viewers in the united states and all around the world. thi this is "new day." it's wednesday, september 9th, it's 6:00 here in new york. and this morning the race to the coronavirus vaccine has just hit a bump. we learned overnight that the pharmaceutical giant astrazeneca has put its phase iii vaccine trial on hold because of an inexplained illness in a study participant. this is not uncommon in large vaccine trials, but it will slow things down and it will lead to questions about other trials. it also just shows that the development of

astrazeneca and oxford university will resume stage three clinical trials in the u.k.tential coronavirus vaccine. they paused testing this week to evaluate one participant who displayed neurological symptoms. meanwhile, covid-19 rates are dropping in the united states. but some universities have become hot spots as students return to campus. let's bring in dr. marty professor of surgery at john hopkins school of medicine author of the price we pace and also a fox news contributor dr. you have been on, you know, evaluator of specialize trial qhs you hear that 18,000 people are involved in this oxford astrazeneca study that one person -- took ill maybe, maybe as a result of maybe not as a result of the treatment, what does that tell you? >> jon that shows how seriously we on data safety monitoring boards take event when is the entire trial is shut down, and the other data safety boards are told to look for the similar symptoms that were seen in this single patient, and there is an intense investigation, and then afterwards it was concluded that the consequences were mild

astrazeneca, the drug company behind it, saying it is a routine action for safety reasons after one of their volunteers suffered a potentially unexplained illness. the drugmaker still hoping to minimize any potential impact on

. >> astrazeneca detiene los estudios contra el covid-19 por una reacciÓn adversa. >> una oportunidada pandemia la han encontrado dos guatemaltecos en su propio hace con un autobÚs convertido en mercado rodante, venden frutas y verduras con todas las precauciones para evitar contagios. >> hola ¿quÉ tal? buenas tardes soy felicidad aveleyra, gracias por estar aquÍ con nosotros, california sigue convertido en un infierno por culpa de los incendios que han destruido mÁs de dos millones de acres, con decenas de focos activos en el centro y sur del estado dorado que dejan viviendas quemadas y evacuaciones masivos de residentes uno de los mÁs grandes es el llamado (palabra en inglÉs) en fresno , ahÍ estÁ francisco fajardo para contaron lo Último, buenas tardes francisco. >> ¿quÉ tal? felicidad, esta es la realidad que nos estamos encontrando en las zonas donde pasaron las llamas viviendas totalmente destruidas algunas sobrevivieron alguna planta la de abajo el balcÓn y en otras nada, quiero enseÑarles esta zona en lo alto de la sierra central de california por aquÍ, hace unas horas pasaron

(fireworks exploding) >>> astrazeneca's oxford university coronavirus vaccine trial is set to resumes the uk. the drug giant's late stage trials were paused last week following an unexplained illness in one of its volunteers. astrazeneca is working with health authorities around the world to determine when trials can resume in other countries. joining me right now to discuss is dr. jane morgan, the clinical director of piedmont health care's coronavirus task force in atlanta, and by the way, she happens to be the mother of one of our fine correspondents, omar jimenez. good to see you, doctor. >> hi. thank you for having me. >> the astrazeneca vaccine is one of three vaccines in late stage, phase three trials, you know, right here in the united states. should this pause give americans confidence that officials are following all the proper protocols? >> i think so, and i think specifically with the astrazeneca, they halted the trial and certainly they're getting that information from their data safety board. so there must have been something significant that they wanted to take a look

meanwhile, astrazeneca hasn't explained why its vaccine trials were paused for safety concerns and why they have restarted in the u.k., but not in the u.s. the company says it's working with the fda to facilitate review of the information, and the fda will decide when the u.s. trial can resume. vaccine expert peter hotez says drug compan transparency is critical is the public confidence in the entire vaccine movement right now on the line? >> not only is the public confidence on the line, but the public confidence in the entire nation's vaccine program is on the line. >> reporter: but tens of thousands have signed up as drug trial volunteers in london, robin powell is still planning to join the astrazeneca trial after the unexplained safety pause. >> i think the risk to me is relatively small and the benefit to the state of man is very great. >> reporter: it is that simple. it is about helping your fellow man. >> exactly so, yes. >> reporter: tonight the most optimistic time line suggests some americans, very few, could start receiving covid vaccines late this year but for most america

so astrazeneca pausing for safety concerns. he's up next we'll check out this morning's biggest s&p winners and losers stay tuned to "squawk box" on cnbc another day, another chance to bounce forward. let's do this. by making internet speeds fast and reliable. so you can keep up with your customers. by ensuring those speeds have wireless internet backup. so if the power goes down, your connection doesn't. and by covering all your connected devices with serious security. so we can handle this. and this. while you get on with this. and this. be fast, be secure. bounce forward. with comcast business. get started with a powerful internet and voice solution for just $64.90 a month. call or go online today. . >>> welcome back to "squawk box. green now. the nasdaq may be giving us a little hope in terms of the overall averages yesterday, it wasn't that bad. it got nasty when it was all said and done. would like to see something like a six handle but we did. pr pretty nice move but has been hit hard we try to keep it all in perspective

. >> and astrazeneca responds on the patient that forced them to stall the testing. >> and nsa turning the head. >> and the state of the apartment rental market in new york city. thursday, september 10, 2020 "worldwide exchange" on cnbc >> good morning, good afternoon, good evening wherever you are watching it is only thursday but feels like we already lived more than a week in the markets. down one day, up in the next futures are in the red dow futures down nasdaq down 85 points right now. the nasdaq did bounce back yesterday. up nearly 3% for its best day since april. 85 nasdaq 100 stocks finished higher on wednesday. le led by gains in zoom and tesla. tesla coming off its worst trading day ever those stocks fractionally down around the world, asia mostly higher after a rough day there european markets are just getting started. julianna tatelbaum is standing by with more and some headlines. good morning >> brian, good morning it looked like we were in for a positive session at the start of trade today but things have turned negative. we are looking at red across the board in europe.

the astrazeneca vaccine is being developed with oxford university and is seen as a front-runner for any potential treatment for covid 19. mitch mcconnell is hoping for a vote on the latest u.s. stimulus package as early as this week. the republican proposal is expected to cost between 500 and $700 billion. the democrats are looking for at least three times that. nancy pelosi told bloomberg the cylinder down packages nowhere near enough. >> what they have is so meager that it insults the intelligence of the american people. it does not solve the problem. again, we know that we have to compromise. we know we have to negotiate in order to region agreement. we all want an agreement. make no mistake about that. get real, mitch mcconnell. karina: in other news, up to half a million people in california have been affected by power cuts as heat waves and power cuts affect the state.